Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) major shareholder Braden Michael Leonard purchased 5,608,306 shares of the company’s stock in a transaction dated Monday, November 14th. The stock was purchased at an average price of $0.69 per share, for a total transaction of $3,869,731.14. Following the completion of the purchase, the insider now owns 5,608,306 shares in the company, valued at $3,869,731.14. The transaction was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Satsuma Pharmaceuticals Stock Up 1.6 %
Shares of Satsuma Pharmaceuticals stock opened at $0.62 on Friday. The stock’s 50-day simple moving average is $5.32 and its 200-day simple moving average is $4.71. Satsuma Pharmaceuticals, Inc. has a 52 week low of $0.59 and a 52 week high of $8.08. The company has a market capitalization of $20.53 million, a price-to-earnings ratio of -0.31 and a beta of 0.42.
Institutional Investors Weigh In On Satsuma Pharmaceuticals
Several large investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of Satsuma Pharmaceuticals by 44.6% in the third quarter. State Street Corp now owns 62,236 shares of the financial services provider’s stock worth $373,000 after purchasing an additional 19,200 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Satsuma Pharmaceuticals by 42.0% in the third quarter. Vanguard Group Inc. now owns 909,390 shares of the financial services provider’s stock worth $5,457,000 after purchasing an additional 269,026 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Satsuma Pharmaceuticals in the third quarter worth about $98,000. Nan Fung Group Holdings Ltd increased its holdings in shares of Satsuma Pharmaceuticals by 24.5% in the third quarter. Nan Fung Group Holdings Ltd now owns 177,900 shares of the financial services provider’s stock worth $1,067,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Satsuma Pharmaceuticals by 16.8% in the third quarter. Dimensional Fund Advisors LP now owns 276,266 shares of the financial services provider’s stock worth $1,658,000 after purchasing an additional 39,731 shares during the last quarter. 72.03% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Satsuma Pharmaceuticals Company Profile
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device.
- Get a free copy of the StockNews.com research report on Satsuma Pharmaceuticals (STSA)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.